Core Viewpoint - The article discusses the termination of the IPO review for Beijing Tianxing Medical Co., Ltd. by the Shanghai Stock Exchange, primarily due to the withdrawal of the sponsor, China International Capital Corporation (CICC) [1] Group 1: Company Overview - Beijing Tianxing Medical Co., Ltd. is a leading domestic company in the field of sports medicine medical devices, with a net profit exceeding 60 million yuan [4] - As of September 30, 2024, the company has obtained 20 Class III medical device registration certificates and 17 Class II medical device registration certificates, along with CE certifications for 15 products [4] Group 2: Financial Performance - The company's revenue for the reporting periods was 73.01 million yuan, 147.97 million yuan, 241.19 million yuan, and 222.93 million yuan [5] - The net profit attributable to the parent company for the periods ending September 30, 2024, December 31, 2023, December 31, 2022, and December 31, 2021, was 64.08 million yuan, 63.58 million yuan, 40.34 million yuan, and -110.25 million yuan respectively [6] - The gross profit margin for the company during the reporting periods was 68.68%, 71.45%, 75.05%, and 69.71% [7] Group 3: Market Position - The company occupies approximately 4% of the sports medicine medical device market in China, ranking first among domestic enterprises [6] Group 4: Customer Base - The top five customers contributed significantly to the company's revenue, with the largest customer accounting for 18.39% of the revenue in the first nine months of 2024 [8] Group 5: Use of IPO Proceeds - The total amount to be raised from the IPO is 880 million yuan, which will be used for projects related to the company's main business, including a smart factory project and product development [8] Group 6: Shareholder Changes - The company had 12 new shareholders added in the year prior to the IPO application, indicating a shift in ownership structure [13]
保荐人独自撤回，IPO终止！